Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.
about
Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?Current approaches to enhance glutamate transporter function and expressionN-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's diseaseConditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomesHuntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.GLT-1: The elusive presynaptic glutamate transporterReal-time imaging of glutamate clearance reveals normal striatal uptake in Huntington disease mouse models.Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3.N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington's disease.Towards an Understanding of Energy Impairment in Huntington's Disease Brain.Specificity of exogenous acetate and glutamate as astrocyte substrates examined in acute brain slices from female mice using methionine sulfoximine (MSO) to inhibit glutamine synthesis.
P2860
Q26770781-3F2D5D4C-D081-4BFB-98E5-10F22E331FDAQ26996723-048978AC-D68C-42DA-9B7C-65EE18550BCCQ28387085-D45A00A0-B36E-4FB5-BDD1-10998AE67A78Q35236862-B4E58123-8135-464B-83EE-DC65A5F6F750Q38663090-B76F4717-8054-4A34-BB77-AE35548CFC5BQ38821169-1825465F-8F72-4A55-9A82-2D5B0B3D227CQ40104806-1CEC5D25-F5DB-4167-957A-05B2DC7040C1Q42289980-A4FE35C6-A11E-4F86-8469-7AEF51FEAEE1Q42868749-72C4D650-A15D-4EB7-A187-9106B5CF5180Q45295137-E5A7B1EE-3824-483D-9AF8-A071DF53939EQ47442924-1D2FF6DA-F76C-4921-8EA9-36E8E7F34C24Q47845319-CFDC89CF-DD95-420D-B610-129F6E273C4F
P2860
Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Decreased expression of GLT-1 ...... ot worsen disease progression.
@ast
Decreased expression of GLT-1 ...... ot worsen disease progression.
@en
type
label
Decreased expression of GLT-1 ...... ot worsen disease progression.
@ast
Decreased expression of GLT-1 ...... ot worsen disease progression.
@en
prefLabel
Decreased expression of GLT-1 ...... ot worsen disease progression.
@ast
Decreased expression of GLT-1 ...... ot worsen disease progression.
@en
P2093
P2860
P356
P1476
Decreased expression of GLT-1 ...... not worsen disease progression
@en
P2093
Geraldine T Petr
Janet M Dubinsky
Kayla C Hussey
Laurel A Schultheis
P2860
P304
P356
10.1111/EJN.12202
P407
P577
2013-04-16T00:00:00Z